Please select the option that best describes you:

What are real world exclusion criteria for the use of lenvatinib + pembrolizumab for advanced endometrial cancer?   

Are there specific clinical or social scenarios that would preclude the use of this treatment?



Answer from: at Community Practice
Sign in or Register to read more

Answer from: at Academic Institution
Sign in or Register to read more